Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Tonix Pharm Holdings (TNXP)

0.2452   0.011 (4.83%) 01-26 00:51
Open: 0.2351 Pre. Close: 0.2339
High: 0.25 Low: 0.2322
Volume: 15,271,871 Market Cap: 122M
Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute, Columbia University, the University of Alberta, and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.25 - 0.252 0.252 - 0.253
Low: 0.227 - 0.229 0.229 - 0.23
Close: 0.248 - 0.25 0.25 - 0.252

Technical analysis

as of: 2022-01-25 4:27:38 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.40     One year: 0.50
Support: Support1: 0.20    Support2: 0.17
Resistance: Resistance1: 0.34    Resistance2: 0.43
Pivot: 0.30
Moving Average: MA(5): 0.25     MA(20): 0.32
MA(100): 0.49     MA(250): 0.86
MACD: MACD(12,26): -0.05     Signal(9): -0.04
Stochastic oscillator: %K(14,3): 11.37     %D(3): 6.06
RSI: RSI(14): 27.75
52-week: High: 2.12  Low: 0.20  Change(%): -75.0
Average Vol(K): 3-Month: 17351  10-Days: 14875

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
TNXP has closed above bottom band by 20.3%. Bollinger Bands are 54.8% wider than normal. The large width of the bands suggest high volatility as compared to Tonix Pharm Holdings's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.

Headline News

Fri, 21 Jan 2022
Why is Tonix Pharmaceuticals Holding Corp. (TNXP) stock gloomy today? - Stocks Telegraph

Tue, 18 Jan 2022
Why AMC and GameStop Are Tumbling Today - Motley Fool

Tue, 04 Jan 2022
Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines - Yahoo Finance

Mon, 03 Jan 2022
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace

Wed, 15 Dec 2021
Tonix Pharmaceuticals Added to the Nasdaq Biotechnology Index - Yahoo Finance

Thu, 21 Oct 2021
Tonix Pharmaceuticals to Participate in BIO-Europe Digital 2021 - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 496
Shares Float (M) 439
% Held by Insiders 0.06
% Held by Institutions 17.96
Shares Short (K) 10,010
Shares Short P. Month (K) 8,650

Stock Financials

EPS -0.277
EPS Est This Year -3.020
EPS Est Next Year -2.470
Book Value (p.s.) 0.500
Profit Margin
Operating Margin
Return on Assets (ttm) -35.3
Return on Equity (ttm) -60.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.161
Qtrly Earnings Growth
Operating Cash Flow (M) -67
Levered Free Cash Flow (M) -56

Stock Valuations

PE Ratio -0.89
PEG Ratio
Price to Book value 0.49
Price to Sales
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2019-10-31
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.